Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genovate Biotechnology Co., Ltd. (4130.TWO)
Hsinchu City, TW
Genovate Biotechnology Co., Ltd. is a Taiwanese enterprise dedicated to the research, development, production, and commercialization of various products. These offerings primarily aim to prevent and treat illnesses resulting from viral and bacterial infections. The company's diverse portfolio extends to drugs, active pharmaceutical ingredients (APIs), intermediates, and specialized release agents, which are crucial for addressing a range of health issues including cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune conditions. Complementing its pharmaceutical offerings, Genovate also manufactures controlled-release Western medicine formulations and cosmetic items. Established in 1982, the company's operations are headquartered in Hsinchu City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.13% | -1.25% | -15.08% | -7.38% | +25.17% | +2.87% | +31.24% | -0.04% | +20.21% | -31.89% | +485.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-3.6% Q1'26: -15.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-56.0% Q1'26: -202.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+1.5% Q1'26: +7.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+2.9% Q1'26: -12.8% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+1.4% Q1'26: -6.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+28.2% Q1'26: +16.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.03× ★ Q1'26: -0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
471.00M
est.
|
497.00M
est.
|
408.00M
est.
|
415.00M
est.
|
472.72M
est: 510.00M (-7.3%)
|
434.25M
est: 501.00M (-13.3%)
|
510.86M
est: 497.00M (+2.8%)
|
492.41M
est: 408.00M (+20.7%)
|
408.00M
408.00M – 408.00M
+0.0% YoY
|
415.00M
415.00M – 415.00M
+1.7% YoY
|
510.00M
510.00M – 510.00M
+22.9% YoY
|
501.00M
501.00M – 501.00M
-1.8% YoY
|
| EBITDA |
54.51M
est.
|
57.52M
est.
|
47.22M
est.
|
48.03M
est.
|
76.19M
est: 59.03M (+29.1%)
|
39.64M
est: 57.98M (-31.6%)
|
69.41M
est: 52.11M (+33.2%)
|
52.88M
est: 42.78M (+23.6%)
|
42.78M
42.78M – 42.78M
+0.0% YoY
|
43.51M
43.51M – 43.51M
+1.7% YoY
|
53.47M
53.47M – 53.47M
+22.9% YoY
|
52.53M
52.53M – 52.53M
-1.8% YoY
|
| EBIT |
18.49M
est.
|
19.51M
est.
|
16.01M
est.
|
16.29M
est.
|
41.01M
est: 20.02M (+104.9%)
|
3.68M
est: 19.67M (-81.3%)
|
31.58M
est: 13.68M (+130.8%)
|
14.14M
est: 11.23M (+25.9%)
|
11.23M
11.23M – 11.23M
+0.0% YoY
|
11.42M
11.42M – 11.42M
+1.7% YoY
|
14.04M
14.04M – 14.04M
+22.9% YoY
|
13.79M
13.79M – 13.79M
-1.8% YoY
|
| Net Income |
58.66M
est.
|
51.01M
est.
|
170.37M
est.
|
94.88M
est.
|
38.73M
est: 53.56M (-27.7%)
|
372.0K
est: 39.63M (-99.1%)
|
25.70M
est: 65.37M (-60.7%)
|
11.68M
est: 207.30M (-94.4%)
|
207.30M
207.30M – 207.30M
+0.0% YoY
|
115.44M
115.44M – 115.44M
-44.3% YoY
|
65.17M
65.17M – 65.17M
-43.5% YoY
|
48.23M
48.23M – 48.23M
-26.0% YoY
|
| SGA |
103.23M
est.
|
108.93M
est.
|
89.42M
est.
|
90.95M
est.
|
98.71M
est: 111.77M (-11.7%)
|
95.49M
est: 109.80M (-13.0%)
|
109.74M
est: 110.82M (-1.0%)
|
112.20M
est: 90.98M (+23.3%)
|
90.98M
90.98M – 90.98M
+0.0% YoY
|
92.54M
92.54M – 92.54M
+1.7% YoY
|
113.72M
113.72M – 113.72M
+22.9% YoY
|
111.71M
111.71M – 111.71M
-1.8% YoY
|
| EPS |
0.51
est.
|
0.44
est.
|
1.48
est.
|
0.83
est.
|
0.35
est: 0.47 (-25.0%)
|
0.00
est: 0.35 (-99.0%)
|
0.22
est: 0.44 (-50.5%)
|
0.10
est: 1.41 (-93.1%)
|
1.41
1.41 – 1.41
+0.0% YoY
|
0.78
0.78 – 0.78
-44.3% YoY
|
0.44
0.44 – 0.44
-43.5% YoY
|
0.33
0.33 – 0.33
-26.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 2/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 2/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-04 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 101.8K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 28.6K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 35.2K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chia-Chen Chu | GM & Director | — | female |
| Hui-Ling Lin | Deputy GM of Finance & Accounting Supervisor | — | — |
| Jen Chen | Chairman & Chief Strategy Officer | — | male |
| Wei-Min Chiang | Senior Director of Administration Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4130.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
